1. 122 PROGNOSTIC FACTORS OF INFECTIONS AND EFFECT OF PRIMARY ANTI-INFECTIOUS PROPHYLAXIS IN MDS PATIENTS TREATED WITH AZACITIDINE (AZA): A PROSPECTIVE STUDY. (April 2015) Authors: Sebert, M.; Aguilar, C.; Ades, L.; Chevret, S.; Lortholary, O.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 123 AZACITIDINE (AZA) COMBINED WITH IDARUBICIN (IDA) IN HIGHER RISK MDS (HRMDS) – RESULTS OF A PHASE I/II STUDY BY THE GFM. Issue 1 (April 2015) Authors: Sebert, M.; Ades, L.; Stamatoullas, A.; Braun, T.; Delaunay, J.; de Renzis, B.; Jeddi, R.; Meddeb, B.; Berger, M. Hunault; Samey, B.; Chermat, F.; Chaffaut, C.; Chevert, S.; Fenaux, P. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 142 MOLECULAR PROGNOSTIC FACTORS IN HIGHER RISK MDS RECEIVING FIRST LINE AZACYTIDINE (AZA). Issue 1 (April 2015) Authors: Ades, L.; Renneville, A.; Marceau, A.; Sebert, M.; Braun, T.; Nibourel, O.; Preudhomme, C.; Fenaux, P. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM. (April 2015) Authors: Ades, L.; Guerci-Bresler, A.; Makhoul, P. Cony; Legros, L.; Delaunay, J.; Recher, C.; Sebert, M.; Lejeune, J.; Chevret, S.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗